[ET Net News Agency, 22 September 2020] China Medical System Holdings Limited (00867)
said the group through its wholly-owned subsidiary signed a distribution, supply and
licence Agreement with medac Gesellschaft fur klinische Spezialpraparate m.b.H (medac) of
the standard-care products marketed in Europe and/or in USA.
The products include Methotrexate pre-filled syringe/pen, a first line alternative
treatment of rheumatoid arthritis and other autoimmune diseases and BCG for intravesical
instillation, a gold standard immunotherapy treatment for non-muscular invasive bladder
cancer.
In accordance with the licence agreement, the group, through its wholly-owned
subsidiary, will gain an exclusive licence to use all relevant intellectual property and
intellectual property rights owned or controlled by medac or its affiliates for the
development, registration and commercialization of the products in mainland China, HKSAR,
Macao SAR and Taiwan (Taiwan is not applicable to the product BCG for intravesical
instillation). (RC)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00867 CMS
Nominal 
7.200 +0.130 (+1.839%) Others
22/09/2020 15:15
CMS (00867) signs agreement with medac
| Remark: | Real time quote last updated: 26/04/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |